It is important to talk to your healthcare team about what side-effects you may be experiencing.

You are able to learn more about side effects from the patient information leaflet which comes with your mediation or via the Yellow Card Scheme.


© 2018 www.DR-web.co.uk is the trading name of DesignRedefined.co.uk Ltd, All Rights Reserved, Registered in England & Wales No: 9945411

Hot Topics

NICE nod for Gilead’s pan-genotypic hepatitis C therapy


Presentations from the PrEP summit now online


US green light for Gilead’s HIV combo


NHS England sets out plans to be first in the world to eliminate Hepatitis C.


Fast-Track London Will Only Work If We Keep Our Foot On The Accelerator


Have your say: contribute to the UN’s work to end TB, HIV and viral hepatitis in the WHO European Region.


The National Institute for Health and Care Excellence (NICE) Issues Positive Guidance for AbbVie’s MAVIRET


Blood samples from the 1950s help rewrite the history of hepatitis C.


Research on HIV cure: Mapping the ethics landscape.


Just because a partner has undetectable viral load, it doesn’t rule out the need for PrEP or PEP


London clinic’s 90% drop in infections could be replicated elsewhere


AbbVie’s MAVIRET® recommended for use within NHS Wales.


Amsterdam PrEP failure patient had unusual course of HIV infectio



Pinterest black large Twitter black large tt blog issuu Picture1 HCV_tile Picture2 NOhep-Logo-Big Twitter_Polls_showed_us NHS_pic_o1 HP_Pic Picture1 Picture2 Picture3 01 11-38DSC_0146 shutterstock_171674909 01 02 03 04 05 08 07 12 13 14 15 16 09 SVR _12 PSP

#hepCtreat Insights

David Rowlands provides an in depth look at his treatment and care experience as well as breaking down the barriers placed on the disease due to stigma and challenging your perceptions on hepatitis C.


95c067_f6a7b585e6de4988ad0602e2a45a1ea2-mv2 Picture1 10 11 Logo_1